Skip to main content

Table 2 Immune-related adverse events (Grade 2–4)

From: Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

  All G2 G3 G4
1.0 Skin toxicities
 Rash/Dermatitis 18 (13.0) 17 (12.3) 1 (0.7) 0 (0)
2.0 Gastrointestinal toxicities
 Colitis 17 (12.3) 11 (8.0) 6 (4.3) 0 (0)
 Hepatitis 17 (12.3) 8 (5.8) 7 (5.1) 2 (1.4)
3.0 Lung toxicities
 Pneumonitis 29 (21.0) 21 (15.2) 8 (5.8) 0 (0)
4.0 Endocrine toxicities
 Hyperthyroidism 35 (25.4) 33 (23.9) 2 (1.4) 0 (0)
 Adrenal insufficiency 3 (2.2) 3 (2.2) 0 (0) 0 (0)
 Pituitary hypophystis 16 (11.6) 12 (8.7) 4 (2.9) 0 (0)
 Diabetes 2 (1.4) 0 (0) 1 (0.7) 1 (0.7)
5.0 Musculoskeletal toxicities
 Arthritis 1 (0.7) 1 (0.7) 0 (0) 0 (0)
 Myositis 1 (0.7) 1 (0.7) 0 (0) 0 (0)
6.0 Renal toxicities 0 (0) 0 (0) 0 (0) 0 (0)
7.0 Nervous system toxities
 Optic neuritis 2 (1.4) 2 (1.4) 0 (0) 0 (0)
8.0 Hematologic toxicities
 Autoimmune hemolytic anemia 3 (2.2) 0 (0) 3 (2.2) 0 (0)
 Lymphopenia 1 (0.7) 0 (0) 1 (0.7) 0 (0)
9.0 Cardiovascular toxicities
 Myocarditis 1 (0.7) 0 (0) 0 (0) 1 (0.7)
 Vasculitis 1 (0.7) 0 (0) 1 (0.7) 0 (0)
 Pericardial effusion 2 (1.4) 0 (0) 2 (1.4) 0 (0)
 Arrhythmia 5 (3.6) 0 (0) 4 (2.9) 1 (0.7)
 Angina pectoris 3 (2.2) 0 (0) 2 (1.4) 1 (0.7)
 Heart failure 1 (0.7) 0 (0) 0 (0) 1 (0.7)
 Pulmonary embolism 1 (0.7) 0 (0) 0 (0) 1 (0.7)
10.0 Ocular toxicities 0 (0) 0 (0) 0 (0) 0 (0)